COMPARISON OF THE RECOVERY AND HALF-LIFE OF A HIGH-PURITY FACTOR-IX CONCENTRATE WITH THOSE OF A FACTOR-IX COMPLEX CONCENTRATE

被引:32
|
作者
POON, MC
ALEDORT, LM
ANDERLE, K
KUNSCHAK, M
MORFINI, M
机构
[1] IMMUNO AG WIEN,MANAGEMENT CLIN RES,A-1221 VIENNA,AUSTRIA
[2] UNIV CALGARY,FOOTHILLS PROV GEN HOSP,DEPT MED,DIV HEMATOL,CALGARY,AB T2N 2T9,CANADA
[3] CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY
[4] POLICLIN CAREGGI,DEPT HEMATOL,FLORENCE,ITALY
[5] POLICLIN CAREGGI,CTR HEMOPHILIA,FLORENCE,ITALY
关键词
D O I
10.1046/j.1537-2995.1995.35495216081.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recovery and half-life estimations were carried out to compare a high-purity factor IX concentrate with an established factor IX complex concentrate. Study Design and Methods:Two high:purity factor IX concentrates, which are identical except for the presence or absence of heparin (Immunine(hep-plus) and Immunine(hep-minus)), were evaluated in two independent crossover studies using an intermediate-purity factor IX complex concentrate (Bebulin) as reference drug. Results: In the Immunine(hep-plus) crossover study (n = 27), Immunine(hep-plus) and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per; kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours. In the Immunine(hep-minus) crossover study (n = 26), Immunine(hep-minus) and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours, Equivalence tests indicated that the recovery and half-life of Immunine, with or without heparin, are equivalent to those of Bebulin. Conclusion: The equivalence in pharmacokinetics and bioavailability indicates that the dosage schedule for Immunine should be the same as or very similar to that of Bebulin. The high specific activity of the former, however, allows administration at lower volumes.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 50 条
  • [11] COAGULATION FACTOR-IX - SUCCESSFUL SURGICAL EXPERIENCE WITH A PURIFIED FACTOR-IX CONCENTRATE
    GOLDSMITH, JC
    KASPER, CK
    BLATT, PM
    GOMPERTS, ED
    KESSLER, CM
    THOMPSON, AR
    HERRING, SW
    NOVAK, PL
    AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (03) : 210 - 215
  • [12] FACTOR-IX CONCENTRATE AND VIRAL HEPATITIS
    BOKLAN, BF
    ANNALS OF INTERNAL MEDICINE, 1971, 74 (02) : 298 - +
  • [13] DISSEMINATED INTRAVASCULAR COAGULATION AFTER FACTOR-IX COMPLEX RESOLVED USING PURIFIED FACTOR-IX CONCENTRATE
    HADLEY, T
    DJULBEGOVIC, B
    ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) : 621 - 622
  • [14] THE USE OF RFVIIA TO TREAT A FACTOR-IX INHIBITOR FOLLOWING ANAPHYLAXIS WITH FACTOR-IX CONCENTRATE
    COLLINS, PW
    FIELDS, P
    GOLDMAN, E
    LEE, CA
    PASI, KJ
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1029 - 1029
  • [15] NO ACTIVATION OF THE COMMON PATHWAY OF COAGULATION AFTER LARGE DOSES OF A HIGH-PURITY FACTOR-IX CONCENTRATE
    MANNUCCI, PM
    BAUER, KA
    GRINGERI, A
    BARZEGAR, S
    SANTAGOSTINO, E
    TRADATI, FC
    ROSENBERG, RD
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 824 - 824
  • [16] STUDIES OF FACTOR-IX CONCENTRATE THERAPY IN HEMOPHILIA
    HULTIN, MB
    BLOOD, 1983, 62 (03) : 677 - 684
  • [17] CLINICAL EXPERIENCE WITH A SWEDISH FACTOR-IX CONCENTRATE
    NILSSON, IM
    AHLBERG, A
    BJORLIN, G
    ACTA MEDICA SCANDINAVICA, 1971, 190 (04): : 257 - +
  • [18] THE STABILITY OF FACTOR-IX CONCENTRATE DURING STORAGE
    SUOMELA, H
    VAHTERA, E
    THROMBOSIS AND HAEMOSTASIS, 1982, 47 (02) : 114 - 115
  • [19] DEVELOPMENT AND CHARACTERIZATION OF THE HIGH-PURITY FACTOR-IX, REPLENINE
    FELDMAN, PA
    HAEMOPHILIA, 1995, 1 : 12 - 15
  • [20] THE DESIGN AND ANALYSIS OF HALF-LIFE AND RECOVERY STUDIES FOR FACTOR-VIII AND FACTOR-IX
    MORFINI, M
    LEE, M
    MESSORI, A
    THROMBOSIS AND HAEMOSTASIS, 1991, 66 (03) : 384 - 386